Примери за използване на Patient's ability to drive на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The influence of SPRAVATO on the patient's ability to drive or operate machinery.
The clinical status of the patient and the adverse reaction profile of dolutegravir should be borne in mind when considering the patient's ability to drive or operate machinery.
The drug does not affect the patient's ability to drive vehicles and mechanisms.
Combination treatment of OLYSIO with other medicinal products for the treatment of CHC may affect a patient's ability to drive and use machines.
There is no evidence that enfuvirtide may alter the patient's ability to drive and use machines, however, the adverse event profile of enfuvirtide should be taken into account(see section 4.8).
Fatigue has been reported in some patients taking venetoclax and should be considered when assessing a patient's ability to drive or operate machines.
However, fluoroquinolones including moxifloxacin may result in an impairment of the patient's ability to drive or operate machinery due to CNS reactions(e.g. dizziness, see section 4.8) or acute and short lasting loss of consciousness(syncope, see section 4.8).
Syncope and retinopathy have been reported in some patients taking INCIVO and should be considered when assessing a patient's ability to drive or operate machines.
This should be considered when assessing a patient's ability to drive or operate machinery.
The clinical status of the patient and the adverse reaction profile of selexipag(such as headache or hypotension) should be kept in mind when considering the patient's ability to drive and use machines.
This should be considered when assessing a patient's ability to drive or operate machinery.
Dizziness has been reported in some patients during treatment with regimens containing darunavir administered with cobicistat and should be borne in mind when considering a patient's ability to drive or operate machinery.
Montelukast is not expected to affect a patient's ability to drive a car or operate machinery.
Fatigue, dizziness and asthenia have been reported in some patients taking IMBRUVICA and should be considered when assessing a patient's ability to drive or operate machines.
The use of L-lysine aescinat may affect the patient's ability to drive vehicles and mechanisms.
The clinical status of the patient and the adverse reaction profile of Kivexa should be borne in mind when considering the patient's ability to drive or operate machinery.
In case of exceeding the recommended dosesthe drug may affect the patient's ability to drive or work in potentially hazardous conditions.
However, fatigue, dizziness and somnolence have been reported in some patients taking EDURANT and should be considered when assessing a patient's ability to drive or operate machinery.
The amount of alcohol in this medicine may impair the patient's ability to drive or use machines.
However, dizziness has been reported in some patients during treatment with regimens containing darunavir co-administered with cobicistat or low dose ritonavir and should be borne in mind when considering a patient's ability to drive or operate machinery(see section 4.8).
The adverse reaction profile of Telzir should be borne in mind when considering the patient's ability to drive or operate machinery(see section 4.8).
The clinical status of the patient and the adverse reaction profile of lamivudine should be borne in mind when considering the patient's ability to drive or operate machinery.
Dizziness has been reported in patients taking Xospata and should be considered when assessing a patient's ability to drive or use machines(see section 4.8).
However, dizziness has been reported in some patients during treatment with regimens containing PREZISTA co-administered with 100 mg ritonavir and should be borne in mind when considering a patient's ability to drive or operate machinery(see section 4.8).
Fatigue and vertigo have been reported in some patients during treatment with PREVYMIS, which may influence a patient's ability to drive and use machines(see section 4.8).
Dizziness has been reported in some patients taking bedaquiline and should be considered when assessing a patient's ability to drive or operate machinery(see section 4.8).
Treatment with regimens containing PREZISTA co-administered with 100 mg ritonavir andshould be borne in mind when considering a patient's ability to drive or operate machinery(see section 4.8).
Adverse reactions such as somnolence and vertigo have been reported in etravirine-treated patients and should be considered when assessing a patient's ability to drive or operate machinery(see section 4.8).
Central nervous system-related adverse events associated with the use of interferon beta(e. g. dizziness)might influence the patient's ability to drive or use machines(see section 4.8).
The clinical status of the patient and the adverse reaction profile of maraviroc should be borne in mind when considering the patient's ability to drive, cycle or operate machinery.